Short report: the activity of pamaquine, an 8-aminoquinoline drug, against sporozoite-induced infections of Plasmodium vivax (New Guinea strains).
It was reported in 1946 that the administration of pamaquine during the incubation period delayed but did not prevent primary attacks of a New Guinea strain of Plasmodium vivax malaria. The observation that none of the four test subjects in this study had relapses has not previously been published and may have important implications for the evaluation of other 8-aminoquinoline compounds against relapsing vivax malaria.
Institute for the Biotechnology of Infectious Diseases, University of Technology Sydney, Gore Hill, New South Wales, Australia. tony.sweeney@uts.edu.au
Anthony W
AW
Sweeney
Charles R B
CR
Blackburn
Karl H
KH
Rieckmann
D000634:Aminoquinolines / Q000266:history* / Q000627:therapeutic use; D000818:Animals; D000962:Antimalarials / Q000266:history* / Q000627:therapeutic use; D001315:Australia; D002986:Clinical Trials as Topic / Q000266:history; D049673:History, 20th Century; D006801:Humans; D016780:Malaria, Vivax / Q000188:drug therapy / Q000266:history* / Q000517:prevention & control; D008889:Military Personnel / Q000266:history; D010966:Plasmodium vivax / Q000187:drug effects* / Q000254:growth & development; D055502:Secondary Prevention; D034101:Sporozoites / Q000472:pathogenicity
D000634:Aminoquinolines; D000962:Antimalarials; C004331:pamaquine